NCI
Neo-Concept International Group Holdings Limited
There isn't enough reported data to score NCI yet.
TSLA
Tesla, Inc.
TSLA's fundamentals are mixed, but it looks expensive: trading at 437x earnings, more than twice its usual 175x. Analysts expect earnings growth, though they disagree widely on how much.
NCI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Stable | |
| Unavailable | |
| Strong |
NCI's balance sheet is currently strong, and its profitability is stable. There isn't enough data to rate its revenue and cash flow.
TSLA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Strong |
TSLA's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is under pressure.
NCI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.5x | $4.21 | -18% |
| Current | 7.9x | $5.12 | — |
| Fair | 13x | $8.38 | +64% |
| Expensive | 107x | $69.87 | +1265% |
Historical ranges are pointers, not guarantees.
NCI has the edge over TSLA in the historical PE scenario, which offers more potential upside but is not a forecast.
TSLA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 60x | $54.70 | -86% |
| Fair | 174x | $158 | -60% |
| Forward | 196x | $397 | — |
| Expensive | 415x | $378 | -4.9% |
| Current | 437x | $397 | — |
Historical ranges are pointers, not guarantees.
TSLA's PE is in its expensive range at 437x. If earnings grow as analysts expect, today's price would be 196x next year's earnings, in its fair range.
NCI Forward outlook
There aren't enough analyst estimates for NCI to show an outlook.
TSLA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for TSLA, with profitability holding steady. However, they disagree widely on these estimates.
NCI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.65 | -96% |
| Q4 2024 | $16.71 | +64% |
| Q4 2023 | $10.19 | -64% |
| Q4 2022 | $28.08 | +128% |
NCI's earnings per share have fallen from their peak: $0.65 over the past year, against $35.52 in mid-2022.
TSLA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.03 | +123% |
| Q3 2026 | $0.91 | -39% |
| Q2 2026 | $1.08 | -38% |
| Q1 2026 | $1.09 | -40% |
| Q4 2025 | $1.08 | -47% |
| Q3 2025 | $1.50 | -59% |
| Q2 2025 | $1.73 | -51% |
| Q1 2025 | $1.82 | -53% |
| Q4 2024 | $2.04 | -53% |
TSLA has the edge over NCI in the latest year-over-year earnings comparison.
NCI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $17.5M | -42% |
| Q4 2024 | $30M | +35% |
| Q4 2023 | $22.2M | +125% |
| Q4 2022 | $9.9M | -7.4% |
| Q3 2022 | $9.9M | -7.4% |
| Q2 2022 | $12.2M | +164% |
| Q1 2022 | $12.2M | +164% |
NCI has the stronger quarterly revenue trend. Revenue is up 77% for NCI versus down 0.2% for TSLA.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 1.3% | -1.6 points |
| Q4 2024 | 4.9% | -2.5 points |
| Q4 2023 | 5.2% | -2.3 points |
| Q4 2022 | 3% | -0.4 points |
| Q3 2022 | 3% | -0.4 points |
| Q2 2022 | 7.5% | +9 points |
| Q1 2022 | 7.5% | +9 points |
| Q4 2021 | 3.3% | N/A |
NCI's operating margin was 1.3% last quarter, down 1.6 points from the same quarter a year ago.
TSLA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $28B | -0.2% |
| Q2 2026 | $28.2B | +26% |
| Q1 2026 | $22.4B | +16% |
| Q4 2025 | $24.9B | -3.1% |
| Q3 2025 | $28.1B | +12% |
| Q2 2025 | $22.5B | -12% |
| Q1 2025 | $19.3B | -9.2% |
| Q4 2024 | $25.7B | +2.1% |
TSLA's revenue has picked up after two years of holding roughly level: $28B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.6% | -3.2 points |
| Q2 2026 | 1.4% | -2.7 points |
| Q1 2026 | 4.2% | +2.1 points |
| Q4 2025 | 5.7% | -0.5 points |
| Q3 2025 | 5.8% | -5 points |
| Q2 2025 | 4.1% | -2.2 points |
| Q1 2025 | 2.1% | -3.4 points |
| Q4 2024 | 6.2% | -2 points |
TSLA's operating margin was 2.6% last quarter, down 3.2 points from the same quarter a year ago, near the bottom of its range since 2019.
NCI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $2.2M | +$2.7M |
| Q4 2024 | -$473.3K | +$6M |
| Q4 2023 | -$6.4M | -$1.6M |
| Q4 2022 | -$4.8M | -883% |
| Q3 2022 | -$4.8M | -883% |
| Q2 2022 | $2.1M | +5597% |
| Q1 2022 | $2.1M | +5597% |
TSLA has the stronger cash trend. Its trailing FCF is down 34% versus its history, compared with NCI at down 156%.
TSLA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5B | -62% |
| Q2 2026 | -$1.1B | -848% |
| Q1 2026 | $1.4B | +117% |
| Q4 2025 | $1.4B | -30% |
| Q3 2025 | $4B | +46% |
| Q2 2025 | $146M | -89% |
| Q1 2025 | $664M | +$3.2B |
| Q4 2024 | $2B | -1.6% |
TSLA still generates free cash flow, though less than at its 2025 peak: $3.3B over the past year.
NCI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.7% | +2.2K shares |
| 1 year | +13% | +7.3K shares |
NCI has 63,500 diluted shares, up 13% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
TSLA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +1M shares |
| 1 year | +0.4% | +15M shares |
| 3 years | +1.4% | +48M shares |
| 5 years | +5.1% | +172M shares |
| Available history | +33% | +886M shares |
TSLA has the edge over NCI on shareholder dilution, with a more favorable share count trend.
NCI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 0.4x | Very low |
| Q4 2024 | 1.3x | Healthy |
| Q4 2023 | 2.7x | Moderate |
| Q4 2022 | 4.0x | Elevated |
| Q2 2022 | 1.4x | Healthy |
| Q4 2021 | 5.8x | High |
NCI's net debt is less than a year of its operating earnings (EBITDA), down from 1.4 years a year ago.
TSLA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.8x | Net Cash |
| Q1 2026 | -0.9x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -1.4x | Net Cash |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.1x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
TSLA has more cash than debt.
NCI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.9 | Neutral |
| Stochastic | 1.9 | Oversold |
NCI's weekly RSI is 34 (neutral) and its Stochastic is 2 (oversold).
TSLA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.3 | Neutral |
| Stochastic | 72.6 | Neutral |
TSLA's weekly RSI is 54 (neutral) and its Stochastic is 73 (neutral).
NCI PE vs Consumer Cyclical Sector
| Metric | NCI | Sector median | Relative |
|---|---|---|---|
| PE | 7.9x | 18x | 56% below |
| PE % | 34 | 24 | 10 pts above |
NCI has the edge over TSLA on valuation relative to its sector.
TSLA PE vs Consumer Cyclical Sector
| Metric | TSLA | Sector median | Relative |
|---|---|---|---|
| PE | 437x | 18x | 2,324% above |
| PE % | 84 | 47 | 37 pts above |
TSLA is trading at 437x earnings, a 2324% premium to the Consumer Cyclical sector's median of 18x.
NCI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.7 | 74% below |
| 20 week MA | $67.8 | 92% below |
| 50 week MA | $117.5 | 96% below |
| 100 week MA | $125.3 | 96% below |
TSLA has stronger trend alignment. NCI is above 0 of 4 weekly averages versus TSLA above 5 of 5.
TSLA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $376.0 | 5.7% above |
| 20 week MA | $364.0 | 9.2% above |
| 50 week MA | $393.6 | 1% above |
| 100 week MA | $372.1 | 6.8% above |
| 200 week MA | $296.9 | 34% above |
TSLA is in an uptrend: it's above all five of its weekly moving averages, and 34% above its 200-week average.
NCI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $601.6 | $167.0 | -72% |
| 2025 | $167.0 | $78.1 | -53% |
| 2026 YTD | $78.1 | $5.12 | -93% |
NCI has finished every year since 2024 lower, and it's down 93% so far in 2026.
TSLA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.7 | $220.6 | +669% |
| 2021 | $220.6 | $355.7 | +61% |
| 2022 | $355.7 | $123.2 | -65% |
| 2023 | $123.2 | $248.5 | +102% |
| 2024 | $248.5 | $431.7 | +74% |
| 2025 | $431.7 | $475.2 | +10% |
| 2026 YTD | $475.2 | $397.5 | -16% |
TSLA has the edge over NCI on returns for 2026, with the stronger performance.